Laden... Bitte warten
Company profile
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA’s innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world’s most common sleep disordered breathing condition.
Source:
Cofisem
-
Last Update:
01 Apr 2025
Key Executives
| Chief Executive Officer | Olivier Taelman | ||||
| Chief Financial Officer | Loïc Moreau | ||||
| Strategy Director | David DeMartino | ||||
| Chief Commercial Officer | Scott Holstine | ||||
| Chief Technology Officer | Bruno Onkelinx | ||||
| Source: Cofisem - Last Update: 01 Apr 2025 | |||||
Key figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 4.521 | 4.348 | 3.084 | 852 | 69 |
| Income from ordinary activities | 4.521 | 4.348 | 3.084 | 852 | 69 |
| Operating income | -58.809 | -45.102 | -32.499 | -26.242 | -11.224 |
| Cost of financial indebtedness net | -2.354 | -135 | 385 | 967 | |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | -59.236 | -43.212 | -31.225 | -27.619 | -12.245 |
| Net income (Group share) | -59.236 | -43.212 | -31.225 | -27.619 | -12.245 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Source: Cofisem - Last Update: 01 Apr 2025 | |||||
Shareholder information
Adresse
Nyxoah SA
Rue Edouard Belin 12
BE-1435
Mont-Saint-Guibert
Belgium
Telefonnummer:
+32 10 45 90 75
Fax:
+32 10 45 90 75
Source:
Cofisem
-
Last Update:
01 Apr 2025